ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Public ClinicalTrials.gov record NCT02319005. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to evaluate the safety and efficacy of revusiran (ALN-TTRSC) in patients with transthyretin (TTR) mediated Familial Amyloidotic Cardiomyopathy. Dosing has been discontinued; patients are being followed-up for safety.
Study identification
- NCT ID
- NCT02319005
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 206 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2014 (Type not available)
- Primary completion
- Mar 30, 2017 (Actual)
- Completion
- Mar 30, 2017 (Actual)
- Last update posted
- Jul 18, 2018
2014 – 2017
United States locations
- U.S. sites
- 41
- U.S. states
- 22
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Trial Site | Bakersfield | California | — | — |
| Clinical Trial Site | Beverly Hills | California | — | — |
| Clinical Trial Site | La Mesa | California | — | — |
| Clinical Trial Site | Los Angeles | California | — | — |
| Clinical Trial Site | San Francisco | California | — | — |
| Clinical Trial Site | Stanford | California | — | — |
| Clinical Trial Site | Torrance | California | — | — |
| Clinical Trial Site | Aurora | Colorado | — | — |
| Clinical Trial Site | Washington D.C. | District of Columbia | 20037 | — |
| Clinical Trial Site | Washington D.C. | District of Columbia | 20422 | — |
| Clinical Trial Site | Tampa | Florida | — | — |
| Clinical Trial Site | Atlanta | Georgia | — | — |
| Clinical Trial Site | Chicago | Illinois | 60611 | — |
| Clinical Trial Site | Chicago | Illinois | 60612 | — |
| Clinical Trial Site | Chicago | Illinois | 60637 | — |
| Clinical Trial Site | New Orleans | Louisiana | — | — |
| Clinical Trial Site | Baltimore | Maryland | 21201 | — |
| Clinical Trial Site | Baltimore | Maryland | 21287 | — |
| Clinical Trial Site | Boston | Massachusetts | 02111 | — |
| Clinical Trial Site | Boston | Massachusetts | 02118 | — |
| Clinical Trial Site | Boston | Massachusetts | 02215 | — |
| Clinical Trial Site | Detroit | Michigan | — | — |
| Clinical Trial Site | Rochester | Minnesota | — | — |
| Clinical Trial Site | St Louis | Missouri | — | — |
| Clinical Trial Site | Newark | New Jersey | — | — |
| Clinical Trial Site | New York | New York | — | — |
| Clinical Trial Site | Rosedale | New York | — | — |
| Clinical Trial Site | The Bronx | New York | — | — |
| Clinical Trial Site | Durham | North Carolina | — | — |
| Clinical Trial Site | Cleveland | Ohio | 44106 | — |
| Clinical Trial Site | Cleveland | Ohio | 44195 | — |
| Clinical Trial Site | Columbus | Ohio | — | — |
| Clinical Trial Site | Philadelphia | Pennsylvania | 19102 | — |
| Clinical Trial Site | Philadelphia | Pennsylvania | 19104 | — |
| Clinical Trial Site | Charleston | South Carolina | — | — |
| Clinical Trial Site | Nashville | Tennessee | — | — |
| Clinical Trial Site | Dallas | Texas | — | — |
| Clinical Trial Site | Fort Worth | Texas | — | — |
| Clinical Trial Site | Houston | Texas | — | — |
| Clinical Trial Site | Richmond | Virginia | — | — |
| Clinical Trial Site | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02319005, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 18, 2018 · Synced Nov 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02319005 live on ClinicalTrials.gov.